Note: This document has been translated from the Japanese original for reference purpose only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect or any other forms of damages arising from the translation.

February 8, 2023

Consolidated Business Results for the Third Quarter Ended December 31, 2022 (Japan GAAP)							
Company:	FUJITEC CO., LTD.	Listed on TSE					
Stock Code:	6406	URL: https://www.fujitec.com					
Representative:	Takao Okada, President and CEO	TEL: +81-72-622-8151					
Contact:	Masashi Tsuchihata, Director, Senior Executiv	ve Operating Officer, General Manager of Finance HQ					
Expected date of filing of quarterly report: February 10, 2023 Expected starting date of dividend payment: —							
Supplementary materials for the quarterly business results: Yes Presentation of the quarterly business results: No							

(Amounts less than one million yen are rounded down)

# 1. Consolidated business results for the third quarter ended December 31, 2022 (April 1, 2022 to December 31, 2022)

(1) Operating results (cumulative)

(1) Operating results (cumulative) (% change from the previous corresponding period)								g period)
	Net sales		Operating income		Ordinary income		Profit attribution owners of	
Nine months ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
December 31, 2022	150,755	10.0	7,201	(40.2)	9,371	(31.2)	5,084	(48.3)
December 31, 2021	137,041	10.5	12,051	20.1	13,618	24.7	9,843	38.7

(Note) Comprehensive income — December 31, 2022: 21,506 million yen [19.8%], December 31 2021: 17,946 million yen [140.9%]

	Net income per share	Diluted net income per share
Nine months ended	Yen	Yen
December 31, 2022	64.04	64.01
December 31, 2021	121.22	121.16

(2) Financial position

	Total assets	Net assets	Shareholders' equity ratio
	Millions of yen	Millions of yen	%
December 31, 2022	244,207	147,559	53.5
March 31, 2022	220,609	140,482	56.9

(Reference) Shareholders' equity — December 31, 2022: 130,627 million yen, March 31, 2022: 125,482 million yen

#### 2. Cash dividends

	Cash dividends per share						
	End of 1st quarter	Total					
	Yen	Yen	Yen	Yen	Yen		
For the year ended March 31, 2022	—	25.00	—	45.00	70.00		
For the year ending March 31, 2023	—	35.00	_				
March 31, 2023 (forecast)				40.00	75.00		

(Note) Revision to the dividend forecasts from the latest announcement: No

Cash dividends for March 31, 2023 (forecast): Regular dividend: 35.00 yen Commemorative dividend: 5.00 yen

# 3. Forecasts of consolidated business performance for the fiscal year ending March 31, 2023 (April 1, 2022 – March 31, 2023)

(% change from the previous corresponding period)

	Net sal	les	Operating income		Ordinary income		Profit attributable to owners of parent		Net income per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
For the year ending March 31, 2023	207,000	10.7	10.500	(23.8)	12,300	(21.7)	7,000	(35.4)	89.44

(Note) Revision to the business performance forecasts from the latest announcement: No

## 4. Other

- (1) Changes in significant subsidiaries during the period
- (changes in specified subsidiaries due to changes in the scope of consolidation): No
- (2) Application of specific accounting procedures for quarterly financial statements: No
- (3) Changes in accounting policies, changes in accounting estimates, and retrospective restatements
  - 1) Changes in accounting policies due to revision of accounting standards: No
  - 2) Changes other than 1), above: No
  - 3) Changes in accounting estimates: No
  - 4) Retrospective restatements: No

(4) Number of shares outstanding (common stock)

1) Number of shares outstanding at the end	Nine months ended December 31, 2022:	Year ended March 31, 2022:
of period (including treasury stock):	82,400,000 shares	82,400,000 shares
	Nine months ended December 31, 2022:	Year ended March 31, 2022:
2) Treasury stock at the end of period:	4,136,298 shares	1,434,800 shares
3) Weighted average number of shares	Nine months ended December 31, 2022:	Nine months ended December 31, 2021:
outstanding during the period:	79,396,238 shares	81,207,647 shares

(Note) Treasury stock as of the end of fiscal year ended March 31, 2022 and as of the nine months ended December 31, 2022 includes shares of

Fujitec Co., Ltd. stock held by the Trust-Type Employee Shareholding Incentive Plan (E-Ship).

Nine months ended December 31, 2022: 73,500 shares, Year ended March 31, 2022: 197,500 shares

### \* This summary is not subject to audit procedures by certified public accountants or audit firms

### \* Explanation regarding appropriate use of business forecasts and other special instructions

The forecasts regarding future performance in this report are based on the information currently available to the Company and certain assumptions that the Company deems to be reasonable at the time this report was prepared. These forecasts are not a guarantee of performance. Actual results may differ significantly from forecasts due to a variety of factors.

For more on business forecasts, see *Explanation of Consolidated Earnings Forecasts and Other Forecasts* on P.5 of *Consolidated Business Results for the Third Quarter (Accompanying Materials).* 

# Table of Contents

2
2
5
5
6
6
8
8
9
10
10
10
11

#### 1. Qualitative Information on Quarterly Financial Performance

#### (1) Explanation of Operating Results

During the nine months ended December 31, 2022, the pace of global economic recovery was generally slow, despite the ongoing transition to a with-COVID-19 era. Continued global inflation caused by soaring resource prices and other factors, as well as monetary policies of various countries aimed at curbing such inflation, were among the factors behind the slow recovery. In China, both domestic and foreign demand remained sluggish due to confusion caused by the reemergence of COVID-19 infections, not to mention the recession linked to real estate. In Japan, business confidence among companies in the non-manufacturing sector improved in response to the recovery of inbound demand and other factors. Confidence in the manufacturing sector weakened due to soaring resource prices and increased raw material costs caused by the sharp depreciation of the yen, resulting in further polarization of business conditions.

In response to these circumstances, the Fujitec Group continued with measures against infectious diseases while implementing our medium-term management plan Vision24. Our sales strategy in the Japanese market reflects the strong performance of AirTap, a touchless elevator button meeting the needs of the new normal. SMA-UP, a new packaged product for modernization, also performed well. In addition, we opened the Osaka Metropolitan Office as a business center in the Kinki area. In the global market, we implemented region-specific sales strategies tailored to the characteristics of each area. Business was active in South Asia, in particular, as evidenced by the receipt of a bulk order for approximately 300 elevators for the Housing & Development Board of Singapore. Under our product and technology strategy, we developed and introduced strategic models that match the maturity level of the market in each country. We developed a new anti-earthquake function for high-rise buildings that shortens the downtime of elevators in the event of an earthquake. We also launched elemori, an online service to confirm elevator and escalator operating information and change settings from a PC or smartphone. Under our production and operations strategy, we reduced production costs through global procurement. In addition, we reduced installation costs by developing innovative installation methods and improving installation skills toward better efficiencies in the field. We began using smart glasses for certain maintenance operations, leveraging remote instructions by skilled technicians, as well as the sharing of technical skills. These efforts are helping improve operational efficiency. We bolstered our global production base by expanding production capacity at facilities in our elevator factory in Taiwan. Under our corporate strategy, we pursued aggressive M&A activities in Japan and overseas in this growth phase for our company, including the acquisition of Elevadores EV International in Mexico. In terms of capital policy, we repurchased company shares to improve capital efficiency. We continued our ESG-related work by improving the effectiveness and transparency of the board of directors to strengthen governance. We developed a sustainability promotion system, including TCFD-compliant information disclosures, registering our products for the European market under the environmental product declaration framework, and declaring our support of the TCFD recommendations. In this way and others, we continued to contribute to the creation of sustainable societies.

As a result, the Fujitec Group recorded business performance for the nine months ended December 31, 2022 as described below.

	FY2021 Q3 (April 1 – December 31, 2021)	FY2022 Q3 (April 1 – December 31, 2022)	Change (%)	Real change, afte excluding the impact of foreign exchange (%)
Orders				
Japan	61,544	62,675	1.8	_
East Asia	56,418	44,292	(21.5)	(31.1
South Asia	14,648	20,534	40.2	24.
The Americas and Europe	18,941	31,828	68.0	47.
Subtotal	151,552	159,330	5.1	-
Adjustments	(7,666)	(10,206)	_	_
Total	143,885	149,123	3.6	_
Order backlog				
Japan	75,396	80,024	6.1	_
East Asia	94,651	97,494	3.0	(10.
South Asia	21,053	26,643	26.6	12.
The Americas and Europe	32,399	44,472	37.3	20.
Subtotal	223,501	248,634	11.2	-
Adjustments	(2,678)	(4,715)	_	-
Total	220,822	243,918	10.5	-

(Amounts less than one million yen are rounded down)

Orders in Japan increased year on year. New installation business remained solid for standard models; however, we saw a reactionary decline due to large project orders received in the same period of the previous fiscal year. Accordingly, we posted a slight performance decline year on year. On the other hand, the Aftermarket Business saw orders increase for modernization projects to upgrade existing elevators and escalators. This increase was due mainly to increased sales of new product and service launches for new lifestyle customers and the new *SMA-UP* modernization package. We also recorded solid sales for maintenance, which services and maintains elevators and escalators.

Despite an increase in new installations in Taiwan and South Korea, overseas orders decreased in East Asia, mainly due to the lockdowns in China and a decrease in new installations during the real estate recession. Performance increased in South Asia. While modernization projects decreased in Singapore and Indonesia, new installations increased in Singapore and India. Orders in the Americas and Europe rose year on year. We saw an increase for new installations in the U.S. and an increase for new installations and modernization projects in the U.K. New installations decreased in Canada, however.

(Amounts less than one million yen are rounded down)

(Through Steps and Steps a						
		FY2021 Q3 (April 1 – December 31, 2021)	FY2022 Q3 (April 1 – December 31, 2022)	Change (%)	Real change, after excluding the impact of foreign exchange (%)	
]	Net sales	137,041	150,755	10.0	_	
	Japan	52,639	53,579	1.8	_	
	Overseas	84,402	97,176	15.1	1.0	
	Operating income	12,051	7,201	(40.2)	_	
	Ordinary income	13,618	9,371	(31.2)	_	
	rofit attributable to owners f parent	9,843	5,084	(48.3)	_	
	Net income per share	121.22 yen	64.04 yen	_	—	

We recorded higher sales and lower operating income year on year for the cumulative consolidated quarter. Although sales increased, operating income decreased in Japan and East Asia. Despite an increase in non-operating income due to an increase in foreign exchange gains stemming from the weaker yen, ordinary income decreased as a result of the decline in operating income. Profit before income taxes decreased mainly due to an impairment loss on goodwill related to a U.K. subsidiary.

As a result, profit attributable to owners of parent decreased year on year.

The following information highlights performance by segment:

Effective as of the consolidated first quarter, Fujitec Argentina S.A. is included in the scope of consolidation. Further, we changed the name of the reporting segment known previously *North America and Europe* to *The Americas and Europe*. The same period of the previous year is also listed under the segment name after the change.

(Amounts less that one minion yet are founded down)									
		Net	sales		Operating income (loss)				
	FY2021 Q3	FY2022 Q3	Change (%)	Real change, after excluding the impact of foreign exchange (%)	FY2021 Q3	FY2022 Q3	Change	Real change, after excluding the impact of foreign exchange	
Japan	54,638	55,489	1.6	—	4,021	(31)	(4,052)	—	
East Asia	58,103	60,823	4.7	(8.6)	5,111	3,398	(1,712)	(2,171)	
South Asia	12,332	17,133	38.9	22.8	1,941	2,848	907	563	
The Americas and Europe	19,763	26,884	36.0	20.0	1,024	1,120	95	(25)	
Subtotal	144,838	160,331	10.7	_	12,099	7,337	(4,762)	_	
Adjustments	(7,796)	(9,575)	_	_	(47)	(135)	(88)	—	
Total	137,041	150,755	10.0	_	12,051	7,201	(4,850)	_	

(Amounts less than one million yen are rounded down)

Japan

Sales increased and profits decreased year on year. Modernization project net sales were lower due to the lingering effects of slow parts procurement in the wake of the first quarter Shanghai lockdowns. Activity increased for new installations, however, due to progress on large projects and solid maintenance sales. We posted an operating loss due to lower profitability in the new installations business caused by sharply higher raw materials costs and lower profits due to fewer modernization project sales.

#### East Asia

Sales increased and profits decreased year on year (both sales and profits decreased when excluding the impact of foreign exchange). Net sales increased due to an increase in new installations in Hong Kong and Korea, as well as an increase in Japanese currency equivalents due to the weak yen. We did see a decrease in new installations in China due to fewer shipments under the lockdowns. Meanwhile, Hong Kong and Korea experienced a decrease year on year, mainly in modernization projects. Operating income decreased, affected by lower profitability in China stemming from lower sales in the new installations business, soaring raw materials costs, and other factors. Lower sales in the Aftermarket Business in Hong Kong also impacted performance.

#### South Asia

Both sales and profits increased year on year. Net sales increased due to performance of the new installations business in Singapore and India, as well as an increase in the Aftermarket Business related to repair work in Singapore. However, new installation business sales decreased in Indonesia. Operating income decreased, mainly due to soaring raw materials costs in the new installations business and a provision for losses on construction contracts, both in India. Sales growth in the Aftermarket Business in Singapore and improved profitability in the new installation business in Indonesia contributed to an increase in operating income.

#### The Americas and Europe

Sales and profits increased year on year (sales increased and profits decreased when excluding the impact of foreign exchange). Net sales increased due to new installation business performance in the U.S. and the U.K. The Aftermarket Business reported firm results across all regions. The addition of Fujitec Argentina S.A. to the scope of consolidation also had a positive impact on performance. Operating income increased due to the conversion to Japanese currency under the weakening yen, despite lower profitability stemming from increased maintenance personnel expenses in the Aftermarket Business in the U.S. and Canada.

#### (2) Explanation of Financial Position

#### a. Financial Position

Total assets as of the end of the cumulative consolidated third quarter amounted to 244,207million yen, an increase of 23,598 million yen compared with the end of the prior consolidated fiscal year. This result was mainly due to increases in notes and accounts receivable-trade, and contract assets, raw materials and supplies, and other inventories.

Total liabilities amounted to 96,647 million yen, an increase of 16,521 million yen compared with the end of the prior consolidated fiscal year. This result was mainly due to increases in notes and accounts payable-trade, short-term debt, and advances from customers.

Net assets amounted to 147,559million yen, an increase of 7,077 million yen compared with the end of the prior consolidated fiscal year. This was mainly due to purchases of treasury stock of 7,962 million yen and cash dividends paid of 6,427 million yen, against 5,084 million yen in profit attributable to owners of parent, an increase of 1,470 million yen in connection with a change in scope of consolidation, an increase of 12,578 million yen in foreign currency translation adjustments, and an increase of 1,932 million yen in non-controlling interests. Our shareholders' equity ratio as of December 31, 2022, was 53.5%, down 3.4 points compared to the end of the prior consolidated fiscal year. Net assets per share amounted to 1,669.06 yen, up 119.23 yen compared with the end of the prior consolidated fiscal year.

#### (3) Explanation of Consolidated Earnings Forecasts and Other Forecasts

We have not made any changes to the consolidated earnings forecasts for fiscal 2022 (April 1, 2022 - March 31, 2023) as announced on November 8, 2022.

# 2. Quarterly Consolidated Financial Statements and Notes

# (1) Quarterly Consolidated Balance Sheets

		(Millions of yen)
	As of March 31, 2022	As of December 31, 2022
Assets		
Current assets		
Cash and deposits	76,956	73,288
Notes and accounts receivable-trade, and contract assets	66,123	80,310
Merchandise and finished goods	3,812	5,197
Work in process	2,281	4,093
Raw materials and supplies	9,004	13,708
Other	8,213	9,809
Allowance for doubtful accounts	(3,119)	(3,157
Total current assets	163,273	183,250
Fixed assets		
Property, plant and equipment		
Buildings and structures, net	19,108	20,347
Machinery and equipment, net	3,864	5,364
Tools, furniture and fixtures, net	2,434	2,805
Land	6,849	6,890
Leased assets, net	640	52
Construction in progress	2,386	93
Total property, plant and equipment	35,283	36,872
Intangible assets		
Goodwill	1,227	1,708
Other	3,609	3,99
Total intangible assets	4,837	5,700
Investments and other assets		
Investments securities	8,356	9,643
Long-term loans receivable	26	2
Other	8,960	8,849
Allowance for doubtful accounts	(127)	(136
Total investments and other assets	17,215	18,384
Total fixed assets	57,335	60,957
Total assets	220,609	244,207

	As of March 31, 2022	As of December 31, 2022	
Liabilities			
Current liabilities			
Notes and accounts payable-trade	16,637	21,612	
Electronically recorded obligations-operating	3,149	4,170	
Short-term debt	3,493	9,718	
Accrued income taxes	2,035	1,681	
Provision for bonuses	3,288	1,981	
Provision for losses on construction contracts	10,169	9,456	
Other provision	2,147	2,307	
Advances from customers	22,428	26,987	
Other	11,342	13,691	
Total current liabilities	74,691	91,607	
Non-current liabilities			
Long-term debt	381	206	
Net defined benefit liability	4,272	4,069	
Other	781	764	
Total non-current liabilities	5,435	5,040	
Total liabilities	80,126	96,647	
Net assets			
Shareholders' equity			
Paid-in capital	12,533	12,533	
Additional paid-in capital	14,474	14,482	
Retained earnings	104,649	104,777	
Treasury stock	(2,267)	(9,933)	
Total Shareholders' equity	129,391	121,860	
Accumulated other comprehensive income			
Valuation difference on available-for-sale securities	2,475	2,266	
Deferred gains or losses on hedges	17	(10)	
Foreign currency translation adjustments	(5,794)	6,783	
Remeasurements of defined benefit plans	(607)	(272)	
Total accumulated other comprehensive income	(3,908)	8,766	
Stock acquisition rights	35	35	
Non-controlling interests	14,964	16,897	
Total net assets	140,482	147,559	
Total liabilities and net assets	220,609	244,207	
		,	

# (2) Quarterly Consolidated Statements of Income and Consolidated Statements of Comprehensive Income Quarterly Consolidated Statements of Income

For the nine months ended December 31, 2021 and December 31, 2022

Cost of sales 104,063 121,043   Gross profit 32,978 29,713   Selling, general and administrative expenses 20,926 22,511   Operating income 12,051 7,201   Other income 623 728   Interest income 623 728   Dividend income 356 218   Foreign exchange gains 259 1,100   Other 570 421   Total other income 1,809 2,470   Other expenses 71 112   Interest expenses 71 112   Provision of allowance for doubtful accounts 93 66   Other 777 112   Total other expenses 242 299   Ordinary income 13,618 9,371   Special gain 15 15   Special gain 13 1,101   Subsidy income 13 1,101   Subsidy income 13 1,101   Loss on sales and retirement of property, plant and equipment		,	(Millions of yen)
Cost of sales 104,063 121,043   Gross profit 32,978 29,713   Selling, general and administrative expenses 20,926 22,511   Operating income 12,051 7,201   Other income 623 728   Interest income 623 728   Dividend income 356 218   Foreign exchange gains 259 1,100   Other 570 421   Total other income 1,809 2,470   Other expenses 71 112   Interest expenses 71 112   Provision of allowance for doubtful accounts 93 66   Other 777 112   Total other expenses 242 299   Ordinary income 13,618 9,371   Special gain 15 15   Special gain 13 1,101   Subsidy income 13 1,101   Subsidy income 13 1,101   Loss on sales and retirement of property, plant and equipment			
Gross profit 32,978 29,711   Selling, general and administrative expenses 20,926 22,511   Operating income 12,051 7,201   Other income 623 728   Interest income 623 728   Foreign exchange gains 259 1,100   Other 570 421   Total other income 1,809 2,477   Other expenses 71 112   Interest expenses 71 112   Provision of allowance for doubtful accounts 93 65   Other 77 111 122   Provision of allowance for doubtful accounts 93 65   Other 77 112 136,618 9,371   Special gain 13,618 9,371 112   Gain on sales of property, plant and equipment 15 15 15   Gain on sales of investment securities 103 10 255   Loss on valuation of investment securities - 0 0   Loss on valuation of invest	Net sales	137,041	150,755
Selling, general and administrative expenses20,92622,511Operating income12,0517,200Other income623728Interest income356218Foreign exchange gains2591,100Other570421Total other income1,8092,470Other expenses71122Provision of allowance for doubtful accounts9366Other77111Total other expenses242299Othar on sales of property, plant and equipment1515Gain on sales of investment securities103100Subsidy income468255Total other loss131,100Loss on sales and retirement of property, plant and equipment2719Impairment loss131,100Loss on valuation of investment securities430Loss on valuation of shares of subsidiaries and associates-1Loss on valuation of investment securities58-Loss on valuation of investment securities58-Loss on related to infectious diseases58-Total special loss1641,122Profit dars pecial loss1641,122Profit before income taxes2,6791,700Deferted taxes expense2,6791,700Deferted taxes expense2,6791,700Deforted taxes expense2,6791,700Deforted taxes expense2,6791,700Profit att	Cost of sales	104,063	121,043
Operating income12,0517,201Other income623728Interest income623728Dividend income626218Foreign exchange gains2591,100Other570421Total other income1,8092,470Other expenses71112Provision of allowance for doubtful accounts9366Other77111Total other expenses71112Provision of allowance for doubtful accounts9365Other77111Total other expenses242299Ordinary income242299Special gain13,6189,371Gain on sales of property, plant and equipment1515Gain on sales of investment securities103100Loss on sales and retirement of property, plant and equipment2715Loss on valuation of investment securities-0Loss on valuation of investment securities-0Loss on valuation of investments in capital of subsidiaries and associates-1Loss on valuation of investments in capital of subsidiaries and associates-1Loss on valuation of investments in capital of subsidiaries and associates-1Loss related to infectious diseases58Total special loss1641.1226.522Profit before income taxes2,6791,700Deferred taxes expense2,6791,700Defer	Gross profit	32,978	29,712
Other income 623 729   Interest income 623 729   Dividend income 356 218   Foreign exchange gains 259 1,100   Other 570 421   Total other income 1,809 2,470   Other expenses 71 122   Interest expenses 71 122   Provision of allowance for doubtful accounts 93 66   Other 77 112   Total other expenses 242 299   Ordinary income 13,618 9,371   Special gain 15 15   Gain on sales of property, plant and equipment 15 15   Gain on sales of investment securities 103 100   Loss on sales and retirement of property, plant and equipment 27 15   Impairment loss 13 1,100 1,000   Loss on valuation of investment securities - 0 0   Loss on valuation of investment securities 22 - -   Loss on v	Selling, general and administrative expenses	20,926	22,511
Interest income623728Dividend income356218Foreign exchange gains2591,100Other570421Total other income1,8092,470Other expenses71122Provision of allowance for doubtful accounts9366Other77111Total other expenses71122Ordinary income242299Ordinary income2439,371Special gain1515Gain on sales of property, plant and equipment1515Gain on sales of investment securities10310Subsidy income468255Total special gain588288Special gain131,107Loss on sales and retirement of property, plant and equipment2719Impairment loss131,107Loss on valuation of investment securities430Loss on valuation of investment securities58-Loss on valuation of investments in capital of subsidiaries and associates-10Loss on valuation of investments in capital of subsidiaries and associates58-Total special loss58-1641,122791,700700Deferred taxes expense2,6791,700Deferred taxes expense3,1582,688Profit attributable to non-controlling interests1,040761	Operating income	12,051	7,201
Dividend income356218Foreign exchange gains2591,100Other570421Total other income1,8092,470Other expenses71122Provision of allowance for doubtful accounts9365Other77111Total other expenses9365Other77112Total other expenses242299Ordinary income13,6189,371Special gain1515Gain on sales of property, plant and equipment1516Gain on sales of investment securities10310Subsidy income468255Total special gain588285Special loss131,107Loss on sales and retirement of property, plant and equipment2715Impairment loss131,107Loss on sales of investment securities-01Loss on valuation of investment securities-01Loss on valuation of investments in capital of subsidiaries and associates58-Total special loss1641,122Profit before income taxes14,0428,527Total special loss-2,6791,700Deferred taxes expense2,6791,700Deferred taxes expense3,1582,688<	Other income		
Foreign exchange gains2591,100Other570421Total other income1,8092,470Other expenses71122Interest expenses71122Provision of allowance for doubtful accounts9366Other77112Total other expenses242295Ordinary income242295Ordinary income13,6189,371Special gain1516Gain on sales of property, plant and equipment1516Gain on sales of investment securities103100Subsidy income468255285Total special gain588285Special loss-0Loss on sales and retirement of property, plant and equipment2715Impairment loss131,107Loss on valuation of investment securities430Loss on valuation of investment securities22-Loss on valuation of investment securities22-Loss on valuation of investments in capital of subsidiaries and associates-11Loss on valuation of investments in capital of subsidiaries22-Total special loss1641,125Profit before income taxes14,0428,527Income taxes expense2,6791,700Deferred taxes expense3,1582,688Profit attributable to non-controlling interests1,04076	Interest income	623	728
Other570421Total other income1,8092,470Other expenses71122Interest expenses71122Provision of allowance for doubtful accounts9365Other77112Total other expenses242295Ordinary income13,6189,371Special gain1515Gain on sales of property, plant and equipment1516Subsidy income468255Total special gain2716Loss on sales and retirement of property, plant and equipment2716Impairment loss131,107Loss on valuation of investment securities430Loss on valuation of investment securities430Loss on valuation of investments in capital of subsidiaries and associates-11Loss on valuation of investments in capital of subsidiaries and associates-11Loss related to infectious diseases58-12Profit before income taxes14,0428,52710Income taxes expense2,6791,70017Deferred taxes expense3,1582,688268Profit attributable to non-controlling interests1,04076	Dividend income	356	218
Total other income1,8092,470Other expenses71122Provision of allowance for doubtful accounts9366Other77112Total other expenses242295Ordinary income13,6189,371Special gain1516Gain on sales of property, plant and equipment1516Gain on sales of investment securities10310Subsidy income468255Total special gain588288Special gain131,100Loss on sales and retirement of property, plant and equipment131,100Loss on sales of investment securities131,100Loss on valuation of investment securities4300Loss on valuation of investments in capital of subsidiaries and associates-11Loss on valuation of investments in capital of subsidiaries and associates-11Loss related to infectious diseases58-11Total special loss1641,12225Profit darke expense2,6791,700100Deferred taxes expense2,6791,700100Deferred taxes expense3,1582,68897Profit attributable to non-controlling interests10,8845,842Profit attributable to non-controlling interests1,04076	Foreign exchange gains	259	1,100
Other expensesInterest expenses71Interest expenses71Provision of allowance for doubtful accounts93Other77Total other expenses242Ordinary income13,618Special gain15Gain on sales of property, plant and equipment15Gain on sales of investment securities103Subsidy income468Special gain588Coss on sales and retirement of property, plant and equipment27Impairment loss13Loss on sales of investment securities43Coss on valuation of investment securities43Loss on valuation of investment securities22Coss on valuation of investments in capital of subsidiaries and associates58Profit before income taxes1641,125Profit attributable to non-controlling interests3,158Profit attributable to non-controlling interests10,400	Other	570	421
Interest expenses71122Provision of allowance for doubtful accounts9365Other77112Total other expenses242296Ordinary income13,6189,371Special gain1515Gain on sales of property, plant and equipment1515Gain on sales of investment securities10310Subsidy income468255Total special gain588288Special loss131,107Loss on sales and retirement of property, plant and equipment2715Impairment loss131,107Loss on valuation of investment securities4300Loss on valuation of investments in capital of subsidiaries and associates-11Loss related to infectious diseases58Total special loss1641,1228,527Loss related to infectious diseases58Total special loss2,6791,7001,700Deferred taxes expense4,78975701Total income taxes3,1582,688975Total income taxes3,1582,688975Total income taxes3,1582,688Profit attributable to non-controlling interests1,040761	Total other income	1,809	2,470
Provision of allowance for doubtful accounts9365Other77112Total other expenses242299Ordinary income13,6189,371Special gain1515Gain on sales of property, plant and equipment1515Gain on sales of investment securities10310Subsidy income468255Total special gain588285Special loss715Loss on sales and retirement of property, plant and equipment2715Impairment loss1311,107Loss on valuation of investment securities430Loss on valuation of shares of subsidiaries and associates-11Loss on valuation of investment securities22-Loss on valuation of investments in capital of subsidiaries and associates58-Total special loss1641,122Profit before income taxes14,0428,527Total special loss2,6791,700Deferred taxes expense2,6791,700Total special loss14,0428,527Total income taxes3,1582,688Profit attributable to non-controlling interests10,8845,842Profit attributable to non-controlling interests1,04076	Other expenses		
Other77112Total other expenses242299Ordinary income13,6189,371Special gain1515Gain on sales of property, plant and equipment1516Gain on sales of investment securities10310Subsidy income468255Total special gain588285Special loss131,107Loss on sales and retirement of property, plant and equipment2719Impairment loss131,107Loss on valuation of investment securities4300Loss on valuation of shares of subsidiaries and associates-11Loss on valuation of investments in capital of subsidiaries and associates22-Total special loss58Loss related to infectious diseases58Total special loss1641,125-Profit before income taxes2,6791,700-Deferred taxes expense2,6791,700-Total special loss1641,125-Profit atributable to non-controlling interests10,8845,845Profit attributable to non-controlling interests1,04076	Interest expenses	71	122
Total other expenses242299Ordinary income13,6189,371Special gain1515Gain on sales of property, plant and equipment1516Subsidy income468259Total special gain588285Special gain588285Special gain588285Special gain2719Impairment loss131,107Loss on sales and retirement of property, plant and equipment2719Impairment loss131,107Loss on sales of investment securities4300Loss on valuation of investment securities4300Loss on valuation of shares of subsidiaries and associates-10Loss on valuation of investments in capital of subsidiaries22-Loss related to infectious diseases58-Total special loss1641,129Profit before income taxes14,0428,527Income taxes expense478975Total income taxes478975Total income taxes3,1582,681Profit10,8845,845Profit attributable to non-controlling interests1,040761	Provision of allowance for doubtful accounts	93	65
Ordinary income13,6189,371Special gain1515Gain on sales of property, plant and equipment1515Gain on sales of investment securities10310Subsidy income468255Total special gain588285Special loss131,107Loss on sales and retirement of property, plant and equipment2715Impairment loss131,107Loss on sales of investment securities-0Loss on valuation of investment securities430Loss on valuation of shares of subsidiaries and associates-1Loss related to infectious diseases58-Total special loss1641,129Profit before income taxes14,0428,527Income taxes expense478975Total income taxes3,1582,688Profit10,8845,845Profit attributable to non-controlling interests1,040761	Other	77	112
Special gain15Gain on sales of property, plant and equipment15Gain on sales of investment securities103Subsidy income468Subsidy income468Special gain588Special loss27Loss on sales and retirement of property, plant and equipment27Impairment loss13Loss on sales of investment securities-Loss on valuation of investment securities43Loss on valuation of investment securities22Loss on valuation of investments in capital of subsidiaries and associates-Total special loss164Interpret taxes expense14,042Profit before income taxes478Profit10,884Profit ttributable to non-controlling interests1,040Profit attributable to non-controlling interests1,040	Total other expenses	242	299
Gain on sales of property, plant and equipment1515Gain on sales of investment securities10310Subsidy income468255Total special gain588285Special loss2715Loss on sales and retirement of property, plant and equipment2715Impairment loss131,107Loss on sales of investment securities4300Loss on valuation of investment securities4300Loss on valuation of shares of subsidiaries and associates-11Loss related to infectious diseases58-Total special loss1641,125Profit before income taxes14,0428,527Total income taxes expense2,6791,706Deferred taxes expense478975Total income taxes3,1582,688Profit10,8845,845Profit attributable to non-controlling interests1,040761	Ordinary income	13,618	9,371
Gain on sales of investment securities103103Subsidy income468259Total special gain588288Special loss2715Loss on sales and retirement of property, plant and equipment2715Impairment loss131,107Loss on sales of investment securities-00Loss on valuation of investment securities4300Loss on valuation of shares of subsidiaries and associates-01Loss related to infectious diseases58-Total special loss1641,129Profit before income taxes478975Total income taxes expense3,1582,661Profit10,8845,845Profit attributable to non-controlling interests1,04076	Special gain		
Subsidy income468259Total special gain588289Special loss719Loss on sales and retirement of property, plant and equipment2719Impairment loss131,107Loss on sales of investment securities-00Loss on valuation of investment securities4300Loss on valuation of shares of subsidiaries and associates-11Loss on valuation of investments in capital of subsidiaries and associates22-Total special loss1641,129Profit before income taxes14,0428,527Income taxes expense2,6791,700Deferred taxes expense478975Total income taxes3,1582,681Profit10,8845,845Profit attributable to non-controlling interests1,040761	Gain on sales of property, plant and equipment	15	15
Total special gain588285Special loss2719Loss on sales and retirement of property, plant and equipment2719Impairment loss131,107Loss on sales of investment securities-0Loss on valuation of investment securities430Loss on valuation of shares of subsidiaries and associates-11Loss on valuation of investments in capital of subsidiaries and associates22-Loss related to infectious diseases58-Total special loss1641,129Profit before income taxes14,0428,527Income taxes expense2,6791,700Deferred taxes expense478975Total income taxes3,1582,681Profit10,8845,845Profit attributable to non-controlling interests1,040761	Gain on sales of investment securities	103	10
Special loss2715Loss on sales and retirement of property, plant and equipment2715Impairment loss131,107Loss on sales of investment securities-0Loss on valuation of investment securities430Loss on valuation of shares of subsidiaries and associates-1Loss on valuation of investments in capital of subsidiaries22-Loss related to infectious diseases58-Total special loss1641,129Profit before income taxes2,6791,700Deferred taxes expense2,6791,700Total income taxes3,1582,681Profit10,8845,845Profit attributable to non-controlling interests1,040761	Subsidy income	468	259
Loss on sales and retirement of property, plant and equipment2719Impairment loss131,107Loss on sales of investment securities-0Loss on valuation of investment securities430Loss on valuation of shares of subsidiaries and associates-10Loss on valuation of investments in capital of subsidiaries and associates22-Loss related to infectious diseases58-Total special loss1641,129Profit before income taxes2,6791,706Deferred taxes expense478975Total income taxes3,1582,681Profit attributable to non-controlling interests1,040761	Total special gain	588	285
Impairment loss131,107Loss on sales of investment securities-0Loss on valuation of investment securities430Loss on valuation of shares of subsidiaries and associates-1Loss on valuation of investments in capital of subsidiaries and associates-1Loss related to infectious diseases58-Total special loss1641,129Profit before income taxes14,0428,527Income taxes expense2,6791,706Deferred taxes expense478975Total income taxes3,1582,681Profit attributable to non-controlling interests1,040761	Special loss		
Loss on sales of investment securities–00Loss on valuation of investment securities4300Loss on valuation of shares of subsidiaries and associates–11Loss on valuation of investments in capital of subsidiaries and associates22–Loss related to infectious diseases58–Total special loss1641,129Profit before income taxes2,6791,700Deferred taxes expense2,6791,700Deferred taxes expense478975Total income taxes3,1582,681Profit attributable to non-controlling interests1,040761	Loss on sales and retirement of property, plant and equipment	27	19
Loss on valuation of investment securities4360Loss on valuation of shares of subsidiaries and associates-14Loss on valuation of investments in capital of subsidiaries and associates22-Loss related to infectious diseases58-Total special loss1641,129Profit before income taxes14,0428,527Income taxes expense2,6791,706Deferred taxes expense478975Total income taxes3,1582,681Profit10,8845,845Profit attributable to non-controlling interests1,040761	Impairment loss	13	1,107
Loss on valuation of shares of subsidiaries and associates-1Loss on valuation of investments in capital of subsidiaries and associates22-Loss related to infectious diseases58-Total special loss1641,129Profit before income taxes14,0428,527Income taxes expense2,6791,706Deferred taxes expense478975Total income taxes3,1582,681Profit10,8845,845Profit attributable to non-controlling interests1,040761	Loss on sales of investment securities	_	0
Loss on valuation of investments in capital of subsidiaries and associates22	Loss on valuation of investment securities	43	0
and associates22Loss related to infectious diseases58Total special loss164Profit before income taxes14,042Income taxes expense2,679Deferred taxes expense478Total income taxes3,158Profit10,884Profit attributable to non-controlling interests1,040		-	1
Total special loss1641,129Profit before income taxes14,0428,527Income taxes expense2,6791,706Deferred taxes expense478975Total income taxes3,1582,681Profit10,8845,845Profit attributable to non-controlling interests1,040761		22	-
Profit before income taxes14,0428,527Income taxes expense2,6791,706Deferred taxes expense478975Total income taxes3,1582,681Profit10,8845,845Profit attributable to non-controlling interests1,040761	Loss related to infectious diseases	58	_
Income taxes expense2,6791,706Deferred taxes expense478975Total income taxes3,1582,681Profit10,8845,845Profit attributable to non-controlling interests1,040761	Total special loss	164	1,129
Deferred taxes expense478975Total income taxes3,1582,681Profit10,8845,845Profit attributable to non-controlling interests1,040761	Profit before income taxes	14,042	8,527
Total income taxes3,1582,681Profit10,8845,845Profit attributable to non-controlling interests1,040761	Income taxes expense	2,679	1,706
Profit10,8845,845Profit attributable to non-controlling interests1,040761	Deferred taxes expense	478	975
Profit attributable to non-controlling interests 1,040 761	Total income taxes	3,158	2,681
	Profit	10,884	5,845
Profit attributable to owners of parent 9,843 5,084	Profit attributable to non-controlling interests	1,040	761
	Profit attributable to owners of parent	9,843	5,084

# Quarterly Consolidated Statements of Comprehensive Income

# For the nine months ended December 31, 2021 and December 31, 2022

	(Millions of yen)
FY2021 Q3 April 1 - December 31, 2021	FY2022 Q3 April 1 - December 31, 2022
10,884	5, 845
24	(208)
62	(34)
6,773	15,568
201	335
7,062	15,661
17,946	21,506
15,647	18,903
2,299	2,603
	April 1 - December 31, 2021 10,884 24 62 6,773 201 7,062 17,946 15,647

## (3) Notes to the Quarterly Consolidated Financial Statements

## (Notes Regarding Assumptions of Going Concern)

Not applicable.

## (Notes on Significant Changes in Shareholders' Equity)

The Company repurchased 2,833,800 shares of treasury stock for 7,961 million yen during the nine months ended December 31, 2022. These purchases were based on a written resolution of the board of directors on March 1, 2022. As a result of this acquisition and other factors, treasury stock amounted to 9,933 million yen at the end of the third quarter of the current fiscal year.

#### (Segment and Other Information)

I Nine months ended December 31, 2021

						(M	lillions of yen)
	Reportable Segments				A 1:	Amount to quarterly	
	Japan	East Asia	South Asia	The Americas and Europe	Total	Adjustments (Note 1)	consolidated statements of income (Note 2)
Net sales							
Sales to external customers	52,711	52,263	12,332	19,734	137,041	_	137,041
Intersegment sales/transfers	1,927	5,840	_	28	7,796	(7,796)	_
Total	54,638	58,103	12,332	19,763	144,838	(7,796)	137,041
Segment income	4,021	5,111	1,941	1,024	12,099	(47)	12,051

Notes 1. Segment income adjustments of (47) million yen include eliminations of intersegment transactions of 0 million yen and inventory adjustments of (48) million yen.

2. Segment income has been adjusted to operating income on the quarterly consolidated statements of income.

#### 2. Information related to impairment of fixed assets, goodwill, etc. by reportable segment

There were no significant events or changes.

#### II Nine months ended December 31, 2022

1. Information on operating revenue and profit (loss) of each reportable segment

						(M	(illions of yen)
	Reportable Segments				Adjustments	Amount to quarterly	
	Japan	East Asia	South Asia	The Americas and Europe	Total	Adjustments (Note 1)	consolidated statements of income (Note 2)
Net sales							
Sales to external customers	53,604	53,164	17,130	26,856	150,755	_	150,755
Intersegment sales/transfers	1,885	7,659	3	27	9,575	(9,575)	_
Total	55,489	60,823	17,133	26,884	160,331	(9,575)	150,755
Segment income (loss)	(31)	3,398	2,848	1,120	7,337	(135)	7,201

Notes 1. Segment income (loss) adjustments of (135) million yen include eliminations of intersegment transactions of 6 million yen and inventory adjustments of (142) million yen.

2. Segment income (loss) has been adjusted to operating income on the quarterly consolidated statements of income.

2. Information related to impairment of fixed assets, goodwill, etc. by reportable segment

(Significant impairment loss on fixed assets)

In the Americas and Europe segment, we recorded an impairment loss of 1,035 million yen on goodwill related to Amalgamated Lifts Limited.

(Significant changes in goodwill)

In the Americas and Europe segment, we recorded an impairment loss on goodwill, resulting in a significant change in the balance of goodwill. As a result, goodwill decreased 1,046 million yen.

During the third quarter of the current consolidated fiscal year, the Company acquired all outstanding shares of Express Lifts Limited through wholly owned subsidiary FUJITEC INDIA PRIVATE LTD., adding the aforementioned company as a consolidated entity. As a result of this transaction, goodwill in the South Asia segment increased 1,554 million yen. The balance of goodwill is based on a provisional calculation since we have not completed allocations of acquisition cost as of the end of the third quarter of the current consolidated fiscal year.

#### 3. Matters Related to Changes in Reportable Segments, Etc.

Effective as of the consolidated first quarter, Fujitec Argentina S.A. is included in the scope of consolidation. Further, we changed the name of the reporting segment known previously *North America and Europe* to *The Americas and Europe*. The same period of the previous year is also listed under the segment name after the change.